Show simple item record

dc.contributor.authorTsavaris, N.en
dc.contributor.authorPrimikirios, N.en
dc.contributor.authorMylonakis, N.en
dc.contributor.authorVarouchakis, G.en
dc.contributor.authorDosios, T.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorTasopoulos, T.en
dc.contributor.authorDritsas, J.en
dc.contributor.authorKosmidis, Paraskevas A.en
dc.creatorTsavaris, N.en
dc.creatorPrimikirios, N.en
dc.creatorMylonakis, N.en
dc.creatorVarouchakis, G.en
dc.creatorDosios, T.en
dc.creatorPavlidis, Nicholasen
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorTasopoulos, T.en
dc.creatorDritsas, J.en
dc.creatorKosmidis, Paraskevas A.en
dc.date.accessioned2018-06-22T09:53:25Z
dc.date.available2018-06-22T09:53:25Z
dc.date.issued1997
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41824
dc.description.abstractFrom June 1984 to October 1995, forty seven consecutive patients (pts) with a confirmed diagnosis of diffuse malignant mesothelioma (MM) of the pleura (41) and peritoneum (6), were treated with cisplatin (CDDP) (24 pts) (Group A), or Doxorubicin (ADM) (14) based chemotherapy (Group B), or a combination of CDDP and ADM (9 pts) (Group C). Chemotherapy for Group A was CDDP 100 mg/m2 Dl with Viblastine 6 mg/m2 Dl, 8 (24 pts), for Group B ADM 40 mg/m2 D I with Vincristine (VCR) 2 mg Dl and DTIC 200 mg/m2 Dl -3 (5 pts) or instead of DTIC Cyclophosphamide 600 mg/m2 Dl instead (pts 4). A Total of 11/47 (23%) of the pts responded to chemotherapy; Group A: I complete and 5 partial responders, Group B: 3 partial responders and Group C: 2 partial responders. Pts with MM of peritoneum showed I complete (Group A) and 4 partial (Group B: 2, Group B: 1, Group C: I) responses, a total of 5/6 (83%). There was no difference in survival time, duration of response and time to progression between the examined groups. A statistically significant difference between responders and non responders in terms of survival was seen: responders 20.8 (3-35), non-responders 5.05 (1-12) months (P = 0.03). Toxicity was acceptable and no treatment-related deaths occurred. Myelosuppression, mild anemia, nausea-vomiting, anorexia and fatigue were the main toxicities. We conclude that CDDP or ADM-based chemotherapy or a combination of both drugs are equally effective in MM.en
dc.language.isoengen
dc.sourceAnticancer Researchen
dc.subjectArticleen
dc.subjectCancer chemotherapyen
dc.subjectCyclophosphamideen
dc.subjectDacarbazineen
dc.subjectHumanen
dc.subjectVincristineen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectFemaleen
dc.subjectMiddle ageden
dc.subjectCancer survivalen
dc.subjectChemotherapyen
dc.subjectPriority journalen
dc.subjectRetrospective studiesen
dc.subjectAlopeciaen
dc.subjectAnemiaen
dc.subjectAnorexiaen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectBone marrow suppressionen
dc.subjectCisplatinen
dc.subjectClinical articleen
dc.subjectDrug efficacyen
dc.subjectFatigueen
dc.subjectNeutropeniaen
dc.subjectVinblastineen
dc.subjectHuman tissueen
dc.subjectProspective studyen
dc.subjectTreatment outcomeen
dc.subjectMaleen
dc.subjectIntravenous drug administrationen
dc.subjectVomitingen
dc.subjectNauseaen
dc.subjectMesotheliomaen
dc.subjectPleura mesotheliomaen
dc.subjectPleural neoplasmsen
dc.subjectDoxorubicinen
dc.subjectDrug toxicityen
dc.subjectPeritoneal neoplasmsen
dc.subjectMalignant mesotheliomaen
dc.subjectPeritoneum mesotheliomaen
dc.titleCombination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A prospective studyen
dc.typeinfo:eu-repo/semantics/article
dc.description.volume17
dc.description.issue5 Ben
dc.description.startingpage3799
dc.description.endingpage3802
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record